Drug Trial Radar · NCT07343245
A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs
Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Feb 22, 2026
Study completion Jun 17, 2026
Sponsor
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Drug-Drug Interaction between DW4421 and three different kinds of NSAIDs
Conditions
- Healthy Adult
Interventions
DW4421Drug
QD
DW4421-N1Drug
BID
DW4421-N2Drug
BID
DW4421-N3Drug
QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax,ssTime frame: Baseline to Day 13 or Day 15
- AUCτ,ssTime frame: Baseline to Day 13 or Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chungbuk National University Hospital
Cheongju-si, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.